PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-51.43%
Both yoy net incomes decline, with AXSM at -4.56%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
31.39%
Less D&A growth vs. AXSM's 308.20%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
0.95%
Less SBC growth vs. AXSM's 33.74%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
2999.17%
Slight usage while AXSM is negative at -206.05%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
284.36%
Lower AP growth vs. AXSM's 1333.42%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
139.25%
Lower 'other working capital' growth vs. AXSM's 1706.28%. David Dodd would see fewer unexpected short-term demands on cash.
3478.66%
Some yoy increase while AXSM is negative at -7996.46%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
582.93%
Some CFO growth while AXSM is negative at -2.71%. John Neff would note a short-term liquidity lead over the competitor.
-3757.14%
Both yoy lines negative, with AXSM at -12.97%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3757.14%
Both yoy lines negative, with AXSM at -24809.92%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-4.55%
We cut debt repayment yoy while AXSM is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.